Risk Stratification for Early Breast Cancer Without Lymph Node Involvement

Primary Clinicopathologic Risk Factors

The American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend that tumor size, histologic grade, hormone receptor status, HER2 status, and proliferative markers (Ki-67) be used to determine relapse risk in node-negative disease 1, 2
Tumors ≤2 cm have a favorable prognosis, while those >2 cm carry a higher risk 3
Low histologic grade (Grade 1) indicates lower risk, while high grade (Grade 3) predicts higher recurrence 1
ER/PR-positive tumors have a better long-term prognosis, though late relapses (>5-8 years) are more common 2, 4
HER2-positive disease requires specific risk stratification and targeted therapy 3, 5
A low Ki-67 proliferation index (<15-20%) indicates lower risk, while an elevated Ki-67 suggests higher proliferative activity and increased recurrence risk 2, 4

The National Comprehensive Cancer Network recommends confirming pathologic features, including tumor size, lymph node status, histologic grade, and lymphovascular invasion presence or absence 1, 6
Evaluating mandatory biomarkers, such as ER/PR status, HER2 status, and Ki-67 proliferative index, is crucial for determining molecular subtype 6, 4, 5

The American Society of Clinical Oncology recommends using validated genomic assays, such as Oncotype DX and MammaPrint, to provide additional prognostic information when clinicopathologic factors leave treatment decisions uncertain 2, 6, 4
Oncotype DX is validated in ER+/HER2-, node-negative disease and provides a recurrence score (RS) as a continuous variable 2, 4, 6
MammaPrint is validated for node-negative and limited node-positive disease and classifies as low or high genomic risk 6, 4

Younger age (<40 years) is associated with higher recurrence risk, and premenopausal status may indicate more aggressive biology 1, 2
The presence of lymphovascular invasion (LVI) increases the risk of both local and distant recurrence and should be routinely assessed on pathology 1

The National Comprehensive Cancer Network recommends a risk-based treatment decision framework, where very low-risk patients may consider endocrine therapy alone, low-intermediate risk patients may consider genomic testing to guide chemotherapy decision, and high-risk patients typically require systemic chemotherapy 2, 6, 3